A cell therapy for viral infections in children and young adults
Part of Immune system & allergy, Infections clinical trials.
This trial tests a special immune cell treatment (R-MVST cells) for children and young adults who have had a stem cell or organ transplant and are fighting stubborn viral infections like EBV, CMV, ADV, or BK virus. The goal is to see if these cells can help control the viruses when standard medicines haven't worked well enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 3 months and 26 years old
- You have had a stem cell or organ transplant
- You have an active infection from one or more of these viruses: EBV, CMV, ADV, or BK
- Your viral infection has not responded well to standard treatments
- You are not on high-dose steroids or certain strong immune-suppressing drugs right now
- You are not pregnant or breastfeeding, and if you can have children, you agree to use birth control
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase (Phase 1) study tests an immune cell treatment (R-MVST) to help people whose immune system has been weakened by a past transplant and who keep getting viral infections reactivated or not responding well to standard treatment. It may help your body control viruses like EBV, CMV, adenovirus, or BK virus.
This trial tests a treatment using specially grown T-cells (a type of immune cell) to fight certain viruses that won't go away with standard medicines. It is for people who have had a stem cell or organ transplant, or who have a weak immune system, and who are struggling with adenovirus, CMV, or EBV infections.
This trial tests a treatment using specially trained immune cells (virus-specific T-cells) to fight stubborn infections with adenovirus, CMV, or EBV in people with weakened immune systems, such as after a stem cell or organ transplant.
This trial tests virus-fighting immune cells (T-cells) made from a donor to treat stubborn CMV or adenovirus infections after a blood and bone marrow transplant. It may help clear the virus when standard antiviral medicines are not working.
This trial tests an immune cell treatment (CMV-specific cytotoxic T cells) for people with a CMV infection that is not improving despite standard antivirals, or who cannot tolerate them. If eligible, the treatment aims to help the body control the virus after transplant-related immune problems.
This trial tests whether adding specially trained immune cells (CTLs) from a related donor to standard treatment helps clear persistent adenovirus or CMV infections after a stem cell transplant. It may be an option if standard antiviral therapy isn't working or causes serious side effects.
Hear when a new Epstein-Barr Virus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.